A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors

Inclusion Criteria:

- Histologically or cytologically documented locally advanced or metastatic solid
tumors for which standard therapies either do not exist or have proven ineffective or
intolerable

- Evaluable disease or disease measurable per Response Evaluation Criteria in Solid
Tumors (RECIST)

- Life expectancy >/= 12 weeks

- Adequate hematologic and end organ function

Exclusion Criteria:

- History of prior significant toxicity from another MEK pathway inhibitor requiring
discontinuation of treatment

- History of prior significant toxicity from another phosphoinositide 3-kinase (PI3K)
or Akt pathway or mammalian target of rapamycin (mTOR) inhibitor requiring
discontinuation of treatment

- Anti-cancer therapy within 28 days prior to first dose of study drug, except as
stated in protocol

- History of type I or type II diabetes mellitus requiring insulin

- Current severe, uncontrolled systemic disease (e.g. clinically significant
cardiovascular, pulmonary, or metabolic disease)

- Clinically significant history of liver disease, current alcohol abuse, or current
known active infection with HIV, hepatitis B or hepatitis C virus

- Active autoimmune disease

- Pregnant or lactating women

- Known brain metastases that are untreated, symptomatic, or require therapy to control
symptoms

- History of glaucoma

- History of retinal vein occlusion